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The CD74-Neuregulin1 (NRG1) fusion gene was recently identified in invasive mucinous 
adenocarcinoma, a malignant type of lung adenocarcinoma, and is considered to be a novel 
driver gene aberration. However, pathogenic functions of the CD74-NRG1 fusion gene are 
unknown, and the mechanism underlying the initiation of cancer stem cells (CSCs) and their 
maintenance in tumors with oncogenic fusion genes is still unclear. In this study, we observed 
that expression of the CD74-NRG1 fusion gene has an activity to increase the population of 
cells with CSC properties. CD74-NRG1 expression facilitated sphere formation of not only 
cancer cells but also non-cancerous lung epithelial cells. Using a limiting dilution assay in a 
xenograft model, we showed that expression of the CD74-NRG1 fusion gene enhanced tumor 
initiation. We observed that CD74-NRG1 expression stimulates phosphorylation of ErbB2/3 and 
activates the phosphatidylinositol 3-kinase (PI3K)/Akt/NF-κB signaling pathway. Furthermore, 
we found that levels of the secreted insulin-like growth factor 2 (IGF2) were increased, and 
phosphorylation levels of the receptor for IGF2, IGF1 receptor (IGF1R), were enhanced in cells 
expressing CD74-NRG1 in an NF-κB activity-dependent manner. These findings suggest that 
the NF-κB activity stimulated by CD74-NRG1 induces the IGF2 autocrine/paracrine circuit. In 
addition, tumor sphere formation induced by the CD74-NRG1 fusion gene was suppressed by 
inhibitors of ErbB2, PI3K, or NF-κB, or an anti-IGF2 antibody. Our study thus provides a 
rationale for developing important treatment options to block the signals that contribute to the 
CSC properties, ErbB/PI3K/Akt/NF-κB pathway, and IGF2 circuit, and to eradicate tumors and 




Cancer stem cells (CSCs) are thought to be responsible for tumor, recurrence, and drug 
resistance (1). It is also believed that many cancer cells are actually differentiated cells 
generated from CSCs, similar to how normal tissues are derived from tissue-specific stem cells 
(1). By definition, CSCs represent a distinct cell population with self-renewal capacity that can 
be prospectively isolated. This population of cancer cells was initially identified in acute 
myeloid leukemia in 1997 (2). Since then, several properties of CSCs have been described, and 
cancer cells that exhibit some CSC properties have been detected in many solid tumors, 
including lung cancer and breast cancer (3-6). Because CSCs are thought to be resistant to 
various stressful conditions such as treatment with chemotherapy and molecular targeted drugs, 
they may survive regardless of tumor shrinkage. After some time, the small number of 
therapy-resistant CSCs may start to grow, leading to recurrence associated with drug resistance. 
Therefore, targeting molecules that play a critical role in maintenance of CSCs is an important 
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therapeutic strategy to eradicate tumors and prevent recurrence. 
Recently, oncogenic fusion genes have been discovered in solid tumors, especially in lung 
cancer. In lung adenocarcinomas, a major type of lung cancer, oncogene fusions frequently 
occur and it may act as driver gene aberrations as well as EGFR or KRAS oncogene mutations. 
The ALK, RET and ROS1 fusion genes have already been reported to be involved in cancer 
development (7-10). Crizotinib, an inhibitor of ALK kinase, is clinically available and has been 
shown to be effective in lung adenocarcinomas with EML4-ALK fusion. Much effort has been 
devoted to developing targeted drugs against the tyrosine kinases in the fusion protein for 
improving therapeutic strategies. However, major concerns regarding recurrence and resistance 
to the targeted drugs against the tyrosine kinases have emerged, resulting in poor prognosis in 
cancer patients (11). In fact, it is largely unknown whether the fusion genes are functional in 
terms of initiation and maintenance of CSCs. If such mechanisms exist, novel therapeutic 
strategies based on these could be developed.  
We and other researchers recently identified the CD74-Neuregulin1 (NRG1) fusion gene in a 
portion of invasive mucinous adenocarcinomas (IMAs) of the lung (12,13). IMA is a highly 
malignant type of lung adenocarcinoma that is mainly caused by KRAS mutations. However, 
this fusion gene is found in cancers that lack other targetable oncogene mutations such as KRAS, 
EGFR, BRAF, and ERBB2. Therefore, the fusion gene may play important roles as a driver gene 
aberration in the development of IMA and has the potential to be a novel therapeutic target. 
CD74 is a transmembrane protein that consists of extracellular, transmembrane, and intracellular 
domains. NRG1, also called heregulin, is a ligand for the ErbB3/human epidermal growth factor 
receptor (HER) 3 tyrosine kinase (14). The CD74-NRG1 protein retains the transmembrane 
domain of CD74 and the epidermal growth factor (EGF)-like domain of NRG1 (NRG III-β3 
form). The NRG III-β3 form protein has a cytosolic N-terminus and a membrane-tethered 
EGF-like domain, and mediates juxtacrine signaling through ErbB2/ErbB3, because the retained 
EGF-like domain has biological activity. Following cleavage at the border of the EGF-like 
domain, NRG1 is also secreted and stimulates ErbB2/ErbB3 in an autocrine/paracrine manner. 
Recently, other types of fusion genes that include a part of NRG1 have been reported not only in 
IMA of the lung but also in ovarian cancer (15). The breakpoints in NRG1 occur in breast cancer 
tissues (16,17), and the resulting fusion gene products are secreted by a breast cancer cell line 
(18). Typically, this part of NRG1 is thought to be able to stimulate ErbB2/ErbB3.  
We previously reported that the NRG1 protein enhances tumor sphere formation by breast 
cancer cells by activating signaling pathways through ErbB2/ErbB3 heterodimers (19). The 
process of sphere formation partly recapitulates the tumorigenic process because only cells with 
CSC properties are thought to be resistant to anoikis, which is apoptosis caused by the loss of 
adhesive survival signals in suspension culture, and form clonal spheroids in sphere culture 
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medium (SCM) which is serum-free but contains several growth factors and hormones (20,21). 
Similar to breast CSCs, lung CSCs can be grown and isolated using the sphere culture protocol 
(6,22,23).  
In this study, we showed that expression of the CD74-NRG1 fusion protein enhances the 
efficiency of tumor sphere formation in vitro and tumor initiating ability in vivo, which are two 
important criteria for cells with CSC properties (24). The hypothesis that CD74-NRG1 initiates 
CSCs in lung tissues was further supported by the observation that expression of the fusion gene 
induced sphere formation by normal lung epithelial cells. We showed that the CD74-NRG1 
protein activates the phosphatidyl inositol 3-kinase (PI3K)/Akt/NF-κB signaling pathway. 
Moreover, the production and secretion of IGF2 protein, which is essential for this tumor sphere 
formation, was dependent on NF-κB activity. The resulting autocrine/paracrine circuit that 
involves IGF2 appears to maintain CSCs. To the best of our knowledge, this is the first study 
reporting that oncogenic fusion gene products indeed function at the level of CSCs. Thus, 
inhibition of this signaling pathway by targeting a single molecule or several molecules in 
combination is an efficient way to treat CD74-NRG1 fusion-positive cancers for eradication of 
cancer cells.  
 
 
Materials and Methods 
Cell Lines and cell culture 
Lung cancer cell line H322 and breast cancer cell line BT20 were purchased from the 
American Type Culture Collection (ATCC). Cells were cultured in RPMI1640 with 10% fetal 
bovine serum (FBS; Gibco) and 1% penicillin-streptomycin (P/S; Nacalai). HEK293T cells 
(ATCC) for lentivirus production were cultured in Dulbecco’s Modified Eagle Medium: 
Nutrient Mixture (DMEM) with 10% FBS and 1% P/S. The cells were maintained in a 
humidified incubator with 5% CO2 at 37°C. 
 
 Western blot analysis 
Immunoblotting was performed using standard procedures as described (19). Anti-ErbB2, 
p-ErbB2, p-ErbB3, Akt, p-Akt, Nanog, Oct-4, Sox2, IKKα, IKKβ, p-IKKα/β, IκBα, p-IκBα, 
IGF1R (receptor for IGF2), and p-IGF1R antibodies were purchased from Cell Signaling 
Technology. Anti-ErbB3 and actin antibodies were purchased from Millipore. Anti-NRG1 and 
CD74 antibodies were purchased from Thermo Scientific and Abcam, respectively. Proteins 
were detected with horseradish peroxidase-conjugated anti-mouse or anti-rabbit antibodies (GE 
Healthcare Life Sciences). 
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 Sphere formation assay 
Sphere formation assay was performed as described (19). Briefly, cells were plated as single 
cells on ultralow attachment 24-well plates (2000~5000 cells/well). They were grown in sphere 
culture medium (SCM) which consisted of serum-free DMEM/F-12 medium (GIBCO) 
supplemented with 20 ng/mL EGF (Millipore), 20 ng/mL basic fibroblast growth factor (bFGF) 
(PeproTech), B27 (GIBCO) and heparin (Stem Cell Technologies) or in DMEM/F-12 medium 
with or without inhibitors or antibodies. LY294002 and anti-IGF2 antibody were purchased 
from Cell Signaling Technology. Lapatinib and Dasatinib were purchased from Selleck 
Chemicals. DHMEQ was a kind gift from K. Umezawa, Aichi Medical School, Japan. Spheres 
with a diameter > 75 μm were counted after 4-7 days. 
 
 Proliferation assay 
 Cells were seeded in a 12-well plate at low density (5000 cells/well), cultured in RPMI1640 
with 10% FBS and 1% P/S. After 4-6 days, cells were harvested and counted. 
 
 Construction of lentiviral vectors for expression of CD74-NRG1 
Expression vectors were constructed as described previously (12). Briefly, full-length cDNAs 
were amplified from tumor cDNA by PCR and then inserted into pLenti-6/V5-DEST plasmids 
(Invitrogen). By using Sanger sequencing, the integrity of inserted cDNA was verified.  
 
 Viral infection 
H322 cells, BT20 cells, and small airway epithelial cells (SAECs) at 60-70% confluence were 
infected with empty lentiviruses or CD74-NRG1-expressing lentiviruses, and then treated with 
blasticidin (Invitrogen) (10, 20, and 5 μg/mL, respectively) for stable expression as described 
previously (12). 
 
 Flow cytometry analysis 
 To identify the breast CSC population, cells were stained with Alexa fluor 647-labeled 
anti-human CD24 and APC-H7 labeled anti-human CD44 antibodies (BD Pharmingen) at 4 °C 
for 20 min. Then cells were analyzed with FACSAria II flow cytometer (BD Bioscience). Dead 
cells were excluded by propidium iodide (PI; Sigma) staining. Data were analyzed with FlowJo 
software (Treestar). 
 
 Quantification of NF-κB activity by Enzyme-Linked ImmunoSorbent Assay (ELISA) 
 Nuclear extracts were prepared with a Nuclear Extract kit (Active Motif), and NF-κB subunit 
p65-DNA binding activity was measured with a TransAM NF-κB p65 Transcription Factor 
  6
Assay kit (Active Motif). All procedures were performed according to the manufacturer’s 
protocol. 
 
Measurement of IGF2 concentration in culture medium 
Cells were seeded in 60 mm dishes and cultured in RPMI medium with 10% FBS. At 60-70% 
confluence, the medium was changed to 1.5 mL of RPMI without FBS. After 24 hr incubation, 
the medium was collected for IGF2 measurement assay. We concentrated 500 μL culture 
medium to 50 μL by using a microcon (Millipore) and then measured the IGF2 concentration 




 Cells were admixed with 50 μl Matrigel (BD Biosciences) and the cell mixture was injected 
into the right flank of 8-week-old nude mice. Tumors larger than 200 mm3 were counted. Tumor 
volume was measured 2 times a week using the following formula: V=1/2(LxW2), where L 
equals length, and W equals width. 
 
Statistical analysis 
 All data are presented as the mean ± SE. The unpaired Student t-test was used to compare 
differences between two samples and values of p < 0.01-0.05 (*), p < 0.001-0.01 (**) or p < 
0.001(***) were considered significant. Tumor initiating frequency was calculated using the 
ELDA Software (25). 
 
Study approval 
 Mice were handled according to the guidelines of National Cancer Center Research Institute, 
Institute of Medical Science, the University of Tokyo and Kanazawa University. The 
experiments were approved by the committees for animal research at National Cancer Center 





・CD74-NRG1 protein induces sphere formation of cancer cells. 
We first examined whether the CD74-NRG1 fusion protein induces sphere formation by lung 
cancer cells. To evaluate the sphere forming ability of CD74-NRG1-expressing cells, we 
infected lentivirus encoding cDNA for the CD74-NRG1 fusion gene, C6;N6 and C8;N6 variants, 
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as reported by Nakaoku et al. (12), into H322 lung cancer cells (Fig. 1A and B). These two 
variants are different in the breakpoints of CD74. We chose H322 cells for this study because 
they have no KRAS mutations. When we cultured these cells in conventional SCM containing 
EGF, bFGF, and B27 supplement, they generated spheres with similar efficiency as cells 
infected with lentivirus carrying a control vector (Fig. 1C and D). Intriguingly, 
CD74-NRG1-expressing cells also generated spheres when cultured in medium without EGF, 
bFGF, or B27 supplement, whereas control cells did not (Fig. 1C and D). Because CSC-related 
function of NRG1 protein was originally identified in breast cancer cells (19), we constructed 
CD74-NRG1-expressing BT20 breast cancer cells to investigate the mammosphere forming 
ability (Fig. 1B). CD74-NRG1-expressing breast cancer cells formed mammospheres even when 
cultured in a medium without EGF, bFGF, or B27 supplement (Fig. 1E and F). These findings 
indicate that the CD74-NRG1 fusion protein induces tumor sphere forming ability in lung and 
breast cancer cells. 
 
・The CSC population increased in CD74-NRG1-expressing cells. 
Next we examined expression levels of the stem cell marker proteins, Nanog, Oct-3/4 and 
Sox2 (26). These stem cell markers were expressed at higher levels in CD74-NRG1-expressing 
H322 cells than in control cells (Fig. 2A). Also, in CD74-NRG1-expressing BT20 cells, 
expression levels of the stem cell markers were higher than in control cells (Fig. 2B). In breast 
cancer, the CD44high/CD24−/low cell population is enriched with cancer cells with stem-like 
properties (3,27). When we investigated the proportion of CD44high/CD24−/low CSC-enriched 
cells by flow cytometry, the percentages of the CD44high/CD24−/low population increased from 
1.94% to 9.47% (C6;N6 variant) or 8.21% (C8;N6 variant) (Fig. 2C). These data further support 
the idea that the CD74-NRG1 fusion gene can enhance CSC properties. On the other hand, the 
proliferation assay revealed that the CD74-NRG1 protein did not significantly induce cell 
growth in adherent cultures (Fig. 2D and E) in the medium containing 10 % FBS or the 
starvation medium with 0.5 % FBS (Fig. 2F). 
 
・The CD74-NRG1 protein activates the PI3K/Akt pathway and controls sphere formation 
ability. 
Because the CD74-NRG1 fusion protein contains the functional domain of NRG1, we 
hypothesized that activation of the ErbB2/ErbB3-regulated pathway contributes to sphere 
formation by CD74-NRG1-expressing cells. To test this hypothesis, we examined the 
phosphorylation levels of ErbB2, ErbB3, and Akt. Expression of the CD74-NRG1 fusion 
protein increased the phosphorylation levels of ErbB2, ErbB3, and Akt compared with vector 
control cells (Fig. 3A). Similar results were observed in CD74-NRG1-expressing BT20 cells 
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(Fig. 3B). These data show that the CD74-NRG1 fusion protein activates ErbB2 and ErbB3 
heterodimer receptors, leading to PI3K/Akt pathway activation. Then, to investigate whether 
activation of the ErbB signaling pathway is important for tumor sphere formation, we checked 
the effect of Lapatinib, an ErbB2 tyrosine kinase inhibitor, on the formation of tumor spheres. 
Lapatinib significantly suppressed the sphere forming ability of CD74-NRG1-expressing H322 
cells (Fig. 3C). This result indicates that signals through ErbB2/ErbB3 receptors play important 
roles in generating tumor spheres by CD74-NRG1-expressing cells. Furthermore, Lapatinib but 
not Dasatinib, a Bcr-Abl tyrosine kinase inhibitor, inhibited tumor sphere formation by 
CD74-NRG1-expressing BT20 cells (Fig. 3D). 
 
・NF-κB activation contributes to sphere formation by CD74-NRG1-expressing cells. 
The NF-κB transcription factor complex, a downstream target of Akt, is activated by the 
NRG-stimulated ErbB2/ErbB3 signaling pathway (19). We then investigated whether NF-κB 
signaling is activated in CD74-NRG-expressing cells. The NF-κB transcription factor complex 
is usually inactive and bound to IκBα, an inhibitory protein, in the cytoplasm (28). IKKα/β are 
the upstream kinases involved in the phosphorylation of IκBα, which results in its ubiquitination, 
proteasome-mediated degradation and the subsequent release of NF-κB. The released NF-κB 
translocates to the nucleus and binds to the κB sequence, where it promotes the transcription of 
various genes. We compared phosphorylation levels of these proteins in 
CD74-NRG1-expressing cells and control cells. In CD74-NRG1-expressing cells, 
phosphorylation levels of IKKα/β and IκBα were increased (Fig. 4A). To examine the 
DNA-binding activity of NF-κB subunit p65 in CD74-NRG1-expressing cells, we quantified the 
intensity of the p65/DNA complex formation by ELISA. Expression of CD74-NRG1 fusion 
protein led to a marked increase in the DNA-binding activity of p65 (Fig. 4B and C). Thus the 
CD74-NRG1 protein-stimulated ErbB2/ErbB3 signaling pathway appears to activate PI3K/Akt, 
leading to NF-κB activation. To test whether activation of PI3K or NF-κB is involved in the 
sphere formation ability of CD74-NRG1-expressing cells, we treated these cells with LY294002 
and DHMEQ, specific inhibitors of PI3K and NF-κB, respectively (29). LY294002 or DHMEQ 
suppressed sphere formation at the similar levels in both H322 and BT20 cells (Fig. 4D and E). 
These data indicate that PI3K/Akt/NF-κB pathway induces tumor sphere forming ability. 
 
・IGF2 plays important roles in sphere formation induced by the CD74-NRG1 fusion 
protein. 
 We have recently found that IGF2 is a downstream target of NF-κB upon stimulation with 
NRG (Tominaga K, Murayama T, et al. unpublished). We next measured secreted IGF2 protein 
in culture medium. The amount of IGF2 protein was increased by CD74-NRG1 expression: 0.91 
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ng/mL and 0.98 ng/mL in cells expressing C6;N6 and C8;N6 variants of CD74-NRG1, 
respectively, compared with 0.71 ng/mL in control cells (n = 2). To investigate whether secreted 
IGF2 is involved in sphere formation, we added IGF2 neutralizing antibody to the medium and 
measured sphere forming efficiency in H322 cells and BT20 cells. The IGF2 neutralizing 
antibody greatly decreased sphere forming efficiency in cells expressing either variant of 
CD74-NGR1 but not in control cells (Fig. 5A, B). In order to check whether IGF1R, a receptor 
for IGF2, is activated by secreted IGF2 that is induced by CD74-NRG1-NF-κB pathway, we 
treated H322 cells expressing C8;N6 variants of CD74-NRG1 with or without DHMEQ and 
examined phosphorylation of IGF1R. We found that the phosphorylation levels of IGF1R were 
increased by expression of CD74-NRG1 protein (Fig. 5C). The increased phosphorylation levels 
of IGF1R were reduced by DHMEQ treatment. These results suggest that the CD74-NRG1 
protein induces sphere formation by activating the PI3K/Akt/NF-κB/IGF2 signaling pathway 
and the IGF2 autocrine/paracrine circuit. 
 
・The CD74-NRG1 fusion gene enhances the tumor initiating ability. 
We next examined whether CD74-NRG1 expression alters the tumor initiating ability using a 
limiting dilution assay in a xenograft model. We injected 1 × 102, 1 × 103, 1 × 104, or 1 × 105 
cells subcutaneously into the right flank of nude mice and observed tumorigenesis. 
CD74-NRG1-expressing H322 cells induced tumor formation more efficiently than control cells 
(Table). However, the tumor growth rate was not significantly increased by CD74-NRG1 
expression (Fig. 6A). These results indicate that the CD74-NRG1 fusion protein has tumor 
initiating ability in vivo. 
 
・The CD74-NRG1 protein induces sphere formation of normal lung epithelial cells. 
Finally, we extended our analysis to non-cancerous cells. Using the lentivirus system, we 
created CD74-NRG1-expressing SAECs, which are immortalized normal lung epithelial cells 
(30). We analyzed the efficiency of sphere formation by these cells in serum-free medium 
without EGF, bFGF or B27 supplement. We found that CD74-NRG1-expressing SAECs formed 
spheres, but control SAECs formed no spheres. These results support the notion that 
CD74-NRG1 initiates CSCs in lung tissues without requiring paracrine factors such as growth 




In this study, we provide evidence that the CD74-NRG1 fusion gene appears to play critical 
roles in the initiation and maintenance of CSC properties. Moreover, we clarified the signaling 
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pathways controlled by the CD74-NRG1 protein. The CD74-NRG1 protein activates the 
ErbB/PI3K/NF-κB pathway, which leads to activation of the IGF2-autocrine/paracrine circuit. 
Thus, oncogenesis may occur at the level of CSCs. It is reasonable to hypothesize that the 
CD74-NRG1 protein confers CSC properties on a few immature, progenitor-like cells rather 
than on the terminally differentiated cancer cells. This finding is important, because therapy 
targeting a single molecule or several molecules in combination in this pathway may eradicate 
tumors and prevent recurrence (Fig. 6D). 
IMAs of the lung constitute 2%—10% of all lung adenocarcinomas in Japan and the United 
States, and are regarded as more malignant than other more common types of lung 
adenocarcinomas (31-33). The KRAS mutation was the only driver aberration found in IMAs. 
However, to improve clinical outcomes, it is necessary to identify novel driver aberrations in 
KRAS-negative IMAs. Following much effort, the CD74-NRG1 fusion gene was identified in 
IMAs in 2014 (12,13). This fusion gene is mutually exclusive with KRAS mutations. In 
CD74-NRG1 fusion-positive tumors, enhanced expression of NRG1 is observed (13). 
CD74-NRG1 is regarded as a driver gene aberration in the development of IMA. Since it is 
recently reported that the fusion genes that include a part of NRG1 are found in ovarian cancer 
(15), the gene alteration involving NRG1 fusion may also occur in other types of tumors.  
 In breast cancer cells and tissues, breaks within NRG1 are frequently detected and may be 
responsible for NRG1 gene fusion (16,17). In fact, DOC4-NRG1 fusion gene is observed in the 
MDA-MB-175 breast cancer cell line (18). In this cell line, NRG1 expression is enhanced 
because of the promoter activity of DOC4 and NRG1 is produced in the culture medium. It is, 
thus, reasonable that some breast cancers are caused by NRG1 gene fusion in a manner similar 
to that observed in CD74-NRG1 fusion-positive IMAs. We are currently trying to identify 
important gene aberrations including gene fusions in breast cancer by using next-generation 
sequencing. 
 In this study, we showed that expression of the CD74-NRG1 protein not only induces sphere 
forming ability in vitro but also enhances the tumor-initiating ability in vivo. These findings 
indicate that this fusion gene is involved in tumor development by inducing CSC properties and 
will be an effective therapeutic target for these tumors. Moreover, we showed that the 
CD74-NRG1 protein activates the PI3K/Akt/NF-κB signaling pathway, leading to IGF2 
autocrine/paracrine circuit to initiate and maintain cells with CSC properties. Our findings 
provide a rationale for developing alternative treatment options, despite the emergence of 
acquired resistance. Because the major acquired resistance mechanisms have been reported to 
be additional mutations in the tyrosine kinase domain of the fusion gene, effective drugs 
targeting the mutant tyrosine kinases have been developed (34). Our findings suggest that 
targeting other molecules in this pathway, rather than the mutant tyrosine kinases themselves, 
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for the initiation and maintenance of CSCs, may be equally effective.  
 It does not seem that expression of the CD74-NRG1 protein strongly stimulates cell growth in 
vitro and in vivo. It is thought that cells with CSC properties grow rather slower than other 
differentiated cancer cells (1). It is thus reasonable that the CSC properties conferred by 
expression of the CD74-NRG1 are not strongly associated with stimulation of cell growth. 
Since the important characteristics of CSCs are resistance to stressful conditions, the 
CD74-NRG1-expressing cancer cells may be more resistant to conventional chemotherapeutics 
than those without expression of the CD74-NRG1 protein. 
  Expression of CD74-NRG1 increased the percentage of CD44high/CD24−/low CSC-enriched 
cells from 1.94% to ~9.5%. The fact that CD44high/CD24−/low CSC-enriched cells are still a 
minor population indicates that expression of the CD74-NRG1 protein is not sufficient for 
conferring CSC properties on all cells. Since the parental BT20 cells do not express the 
CD74-NRG1 gene, it is possible that the intrinsic CSC properties carried by a subpopulation of 
BT20 cells are conferred by other gene alterations. However, the increase in the population of 
BT20 cells with CSC properties by enforced CD74-NRG1 expression may indicate that the 
intrinsic CSC properties are conferred on more cells by the IGF2 autocrine/paracrine circuit. It 
is known that even within a cancer cell line, there are immature cell populations with CSC 
properties and other differentiated cancer cell populations (27, 35). It is thus possible that 
expression of the CD74-NRG1 protein shifts the cell population toward more cells with CSC 
properties than differentiated cells. 
 The mechanisms underlying the production of IGF2 by NF-κB are unclear. We recently found 
that NRG stimulates the transcription of IGF2 mRNA in an NF-κB-dependent manner 
(Tominaga K, Murayama T, et al. unpublished). Several binding site motifs for NF-κB are 
present in the IGF2 promoter sequence. Thus, increased NF-κB activity may lead to production 
of IGF2 at the transcriptional level. 
In conclusion, our results suggest that PI3K/Akt/NF-κB/IGF2 signaling activated by the 
CD74-NRG1 fusion protein is involved in CSC maintenance and tumor initiation. Therefore, 
development of efficient inhibitors or antibodies targeting the molecules in this pathway is 
anticipated to improve the prognosis of IMA patients with the CD74-NRG1 fusion gene. Further, 
establishment of effective diagnostic methods capable of detecting this gene aberration is 
necessary. A therapeutic strategy that targets cells with CSC properties by inhibiting 
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Results of limiting dilution assay of vector- or CD74-NRG1-transduced H322 cells 
 
H322 cells 
  Cells (per site) 
Tumor initiating cell 
frequency estimate Probability  102 103 104 105 
Empty vector 1/6 3/6 6/6 5/6 13,101 
5.27E-06CD74-NRG1 














Figure 1. The CD74-NRG1 fusion protein induces sphere formation. 
A, schematic representations of wild-type proteins and the CD74-NRG1 fusion protein (C6;N6 
variant: top and C8;N6 variant: bottom). TM, transmembrane domain, Blue arrows indicate the 
breakpoints. B, expression of the CD74-NRG1 fusion protein in H322 (left) and BT20 (right) 
cells were confirmed with immunoblot analysis. C and D, sphere formation assay with vector- 
or CD74-NRG1-transduced H322 cells. Cells were treated with no growth factors or 
EGF/bFGF/B27 (N.T.: not treated, n = 4, ***P < 0.001). Scale bar = 100 μm. E and F, sphere 
formation assay with vector- or CD74-NRG1-transduced BT20 cells. Cells were treated with no 
growth factors or EGF/bFGF/B27 (N.T.: not treated, n = 4, ***P < 0.001). Scale bar = 100 μm. 
 
Figure 2. The CD74-NRG1 fusion protein increases the proportion of CSCs. 
A, expression levels of Nanog, Oct3/4 and Sox2 in H322 cells with each vector were 
determined by immunoblotting. B, expression levels of Nanog, Oct3/4 and Sox2 in BT20 cells 
with each vector were determined by immunoblotting. C, vector- or CD74-NRG1-trasduced 
BT20 cells were stained with CD44 and CD24 antibodies and then subjected to flow cytometry 
analysis. D and E, H322 cells (D) or BT20 cells (E) with each vector were seeded in a 12-well 
plate (5,000 cells/well). Cells were cultured in 10 % FBS and then harvested and counted after 4 
or 6 days (n = 4). F, H322 cells were seeded described in (D). Cells were starved in 0.5 % FBS 
and then harvested and counted after 6 days (n = 4).  
 
Figure 3. Activation of the PI3K/Akt pathway induces sphere formation. 
A and B, phosphorylation levels of ErbB2, ErbB3 and Akt in vector- or 
CD74-NRG1-transduced H322 cells (A) and BT20 cells (B) were determined by 
immunoblotting. C and D, sphere formation assay with vector- or CD74-NRG1-transduced 
H322 cells (C) or BT20 cells (D). Cells were incubated with or without 100 nM Lapatinib or 
100 nM Dasatinib (N.T.: not treated, n = 4, ***P < 0.001).  
 
Figure 4. NF-κB is activated by CD74-NRG1 expression. 
A, phosphorylation levels of IKKα/β and IκBα in vector- or CD74-NRG1-transduced H322 
cells were determined by immunoblotting. B and C, the DNA binding activities of p65 in H322 
(B) and BT20 (C) cells were quantified by ELISA (n = 3, *P < 0.05, **P < 0.01) D and E, 
sphere formation assay with vector- or CD74-NRG1-transduced H322 (D) and BT20 (E) cells. 
Cells were incubated with or without 1 μg/mL DHMEQ or 1 μM LY294002 (N.T.: not treated, n 
= 4, ***P < 0.001).  
 
Figure 5. Secreted IGF2 is crucial for sphere formation. 
  17
A and B, sphere formation assay with vector- or CD74-NRG1-transduced H322 (A) and BT20 
(B) cells. Cells were incubated with 10 μg/mL anti-IGF2 neutralizing antibody (NAb) (N.T.: not 
treated, data are the mean ± SE; n = 4, ***P < 0.001). C, H322 cells expressing C8;N6 were 
incubated with or without 5 μg/mL DHMEQ for 24hr. Phosphorylation levels of IGF1R were 
determined by immunoblotting. 
 
Figure 6. The CD74-NRG1 fusion protein enhances the tumor initiating ability of cancer 
cells. 
A, tumor growth curves of vector- or CD74-NRG1-transduced H322 cells when injected with 1 
× 104 cells (n = 6). B and C, sphere formation assay with vector- or CD74-NRG1-transduced 
SAECs. (N.T.: not treated, n = 4, ***P < 0.001). Scale bar = 100 μm. D, The CSC maintenance 
signals. The CD74-NRG1 protein activates PI3K/Akt/NF-κB pathway to induce IGF2 
autocrine/paracrine circuit for maintenance of CSCs. Blocking one or several molecules in the 
pathways would be effective for eradicating tumors. 






